Stoke Therapeutics (STOK) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zenas BioPharma (ZBIO) has outperformed Stoke Therapeutics (STOK) over the past year, losing 1.8% versus a loss of 21.5%. Zenas BioPharma is the larger company by market cap ($1.78 billion vs $1.60 billion), about 1.1 times the size, while Stoke Therapeutics is growing revenue faster (+404.5% vs +100.0%). Stoke Therapeutics converts more of its revenue into profit, with a net margin of -3.7% versus -3777.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | STOK | ZBIO |
|---|---|---|
| Share price | $24.74 | $27.26 |
| Market cap | $1.60B | $1.78B |
| 1-day change | +3.30% | +3.89% |
| YTD return | -24.54% | -24.92% |
| 1-year return | -21.48% | -1.80% |
| 5-year return | +1.83% | — |
| EPS (TTM) | $-3.49 | $-9.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $184.42M | $10.00M |
| Revenue growth (YoY) | +404.50% | +100.00% |
| Net income (latest FY) | $-6.88M | $-377.74M |
| Operating margin | -11.16% | -3830.57% |
| Net margin | -3.73% | -3777.37% |
| 52-week high | $40.22 | $44.60 |
| 52-week low | $20.32 | $13.50 |
| Distance from 52-week high | -38.49% | -38.88% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +87.79% | +75.64% |
| Average volume | 858.95K | 733.34K |
| Shares outstanding | 64.53M | 65.18M |
| Employees | 170 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZBIO has outperformed STOK by 19.7 percentage points over the past year.
- Stoke Therapeutics is more profitable, keeping -3.7 cents of every revenue dollar as net income versus -3777.4 cents for Zenas BioPharma.
- Stoke Therapeutics grew revenue faster in its latest fiscal year (+404.50% vs +100.00%).
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
STOK vs ZBIO FAQ
Which is bigger, Stoke Therapeutics or Zenas BioPharma?
Zenas BioPharma (ZBIO) is larger, with a market capitalization of $1.78B compared with $1.60B for Stoke Therapeutics (STOK).
Which stock has performed better over the past year, STOK or ZBIO?
ZBIO returned -1.80% over the past 12 months, compared with -21.48% for STOK (price return, excluding dividends). Past performance does not predict future results.
Are Stoke Therapeutics and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.